Pharma Foods International (TYO:2929) will establish Cadasil Drug Discovery Research Department in collaboration with the National Cerebral and Cardiovascular Center, according to a Wednesday filing on the Tokyo Stock Exchange.
Cadasil, a genetic vascular disease with no established cure, is linked to NOTCH3 gene mutations, leading to migraines, strokes, and dementia.
The National Cerebral and Cardiovascular Center, a research institute for cardiovascular diseases, is conducting Phase 2 clinical trials on adrenomedullin peptide as a potential treatment.
Pharma Foods will apply its expertise in peptide research to develop new therapies for the disease, aligning with its broader mission of advancing healthcare innovations.
Price (JPY): $940.00, Change: $-10, Percent Change: -1.05%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。